Company Overview and News

122
Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

2018-09-03 seekingalpha - 2
The sequential decline is entirely driven by special effects. Endless opportunities in August caused me to trim and sell various smaller holdings.
BZUN HUYA XOM RDSB RDSA EQM AVGO SO CBAUF BABA WCAGY BP JNJ RYDBF JD WFCNP SOJA MOMO NEP ANET WB AAPL CF RYDAF MCD WFC RDS.B RDS.A WRCDF TGT V T PEP IQ SBUX

 
Commonwealth Bank Of Australia ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-08 seekingalpha
The following slide deck was published by Commonwealth Bank of Australia ADR in conjunction with their 2018 Q4 earnings call.
CBAUF CMWAY

63
Dividend Portfolio Review: Busy Earnings Season, Heavy Buying, Growing Dividends

2018-08-07 seekingalpha
July, being arguably one of the quietest months for dividend income in my portfolio, showed great strength with dividend income hitting $195.02, up 58% Y/Y and down 21% sequentially.
WFCNP FB AAPL INTC ABBV MCD WFC CBAUF DDAIF TGT V JNJ ABBV

627
Dividend Portfolio Review: New Dividend Record

2018-06-18 seekingalpha
May set a new record with $369 in dividend come, up 33% Y/Y and 109% sequentially.
JD WFCNP TXN BZUN MOMO RDSB NVDA RDSA AMZN AAPL VNNVF RYDAF INTC BGS MCD WFC RDS.B RDS.A GILD CBAUF VONOY TGT V JNJ MU RYDBF

419
Road To Financial Independence: My April 91-Stock Portfolio Review

2018-05-31 seekingalpha
The April earnings season was in full swing and led to big selloffs in classic dividend stocks.
WFCNP TWX MOMO KMI AAPL CSCO INTC KMR CVB ABBV MCD WFC CBAUF DDAIF TWC TGT V JNJ MU ABBV APR APRLY KMRFZ

486
Road To Financial Independence: My March 89-Stock Portfolio Review

2018-04-11 seekingalpha - 2
Volatility has been in full swing in March, leading to massive selloffs in some of my core stocks. This was another excellent opportunity to add heavily to my holdings.
WFCNP FB SIEGY MOMO RDSB NVDA RDSA TD WMT CM AAPL RYDAF TD BGS ABBV MCD MO WFC RDS.B RY RDS.A TNTTF CBAUF TGT V RY JNJ RYDBF TSLA ABBV

418
Road To Financial Independence: My February 88-Stock Portfolio Review With Big Apple Purchase

2018-03-13 seekingalpha
February saw the first meaningful correction in the U.S. stock market in quite some time. That was an excellent opportunity to add heavily to my holdings.
SOJA WFCNP TWX MOMO NVDA AAPL ABBV MCD WFC SO CBAUF DDAIF TGT V T PEP JNJ TSLA ABBV OHI PFE

38
Will Slow GDP Growth Take a Beating on Australia ETFs?

2018-03-12 zacks
Australia’s GDP grew slower than expected by economists, as bad weather led to a fall in exports. Construction activity further dragged down the GDP growth, weighing on gains provided by strong household activity.
WBC BLT TAH WLK BHPBF CBAUF NAB NASXF WEBNF NABZY WBK CMWAY NAUBF TABCF WBC BHP CBAUY BBL BHP HVN BHPLF HNORY TACBY

1
The Commonwealth Bank At Attractive Levels

2018-03-12 seekingalpha
The Commonwealth Bank's stock price has fallen on the back of several scandals, including breaches of anti-money laundering laws.
GNWTY GMA GWRHF CBAUF AAGIY AAIGF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 621503002